medigraphic.com

2004, Número s2

<< Anterior Siguiente >>

Arch Cardiol Mex 2004; 74 (s2)


¿Son la diabetes mellitus tipo 2 y el síndrome metabólico una misma enfermedad? Consideraciones acerca de la prevención de la enfermedad cardiovascular aterosclerosa

Fernández BCL

Idioma: Español
Referencias bibliográficas: 20
Paginas: 261-266
Archivo PDF: 80.10 Kb.


RESUMEN

El síndrome metabólico es el factor de riesgo cardiovascular más frecuente en México, razón por la cual debiera considerarse factor de riesgo mayor. Sin embargo, el enfoque tradicional de evaluación del riesgo coronario no incluye a varios de los elementos del síndrome, tales como la hipertrigliceridemia, las alteraciones del metabolismo de la glucosa previas a la diabetes, la obesidad, ni a los factores de riesgo emergentes estrechamente relacionados al síndrome, entre los que están la microalbuminuria y los niveles de proteína C reactiva de alta sensibilidad. Necesitamos saber si al incluir a estos elementos podemos mejorar la predicción y prevención de desenlaces coronarios en personas con síndrome metabólico. En países como México donde el síndrome metabólico está presente en más de la mitad de las personas mayores de 50 años y en la mayoría de los pacientes con síndromes coronarios agudos, debemos ir más allá del control de los factores de riesgo mayor tradicionales, con el fin de frenar el constante aumento de la epidemia de las enfermedades aterosclerosas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Diabetes Mellitus: A major risk factor for Cardiovascular disease. A joint editorial statement by the American Diabetes Association; the National Heart, Lung and Blood Institute; the Juvenile Diabetes Foundation international; the National Institutes of Diabetes, Digestive and Kidney Diseases, and the American Heart Association. Circulation 1999; 100: 1132-1133.

  2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation and treatment of high blood cholesterol in adults (Adults Treatment Panel III). JAMA 2001; 285: 2486-2497.

  3. Aguilar Salinas C, Rojas R, Gómez Pérez FJ, Valles V, Ríos Torres JM, Franco A, Olaiz G, Rull JA, Sepúlveda J: Prevalence of the metabolic syndrome in Mexico: results from a population based study. Arch Med Res 2004, (in press).

  4. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 and older. Diabetes 2003; 52: 1210-1214.

  5. Cohen JD, Vázquez G, Eberly LE, Prineas RJ, Zhi X, Kuller L, Neaton JD: Impact of the Metabolic Syndrome on cardiovascular disease mortality. The Multiple Risk Factor Intervention Trial (MRFIT) 18 year follow-up experience. Circulation 2003; 108 (S-IV): IV-727.

  6. Tenerz A, Norhammar A, Silveira A, Hamsten A, Nilsson G, Ryden L, Malmberg K: Diabetes, insulin resistance, and the Metabolic Syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 2003; 26: 2770-2776.

  7. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C: for the conference participants. Definition of metabolic syndrome. Report of the National Heart, Lung and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004; 109: 433-438.

  8. Ridker PM, Buring JE, Cook NR, et al: C-Reactive Protein and the Metabolic Syndrome, and Risk of Incident Cardiovascular Events. An 8-year Follow up of 14719 Initially Healthy American Women. Circulation 2003; 107: 391-397.

  9. Opie LH, Parving HH: Diabetic nephropathy. Can renoprotection be extrapolated to cardiovascular protection? Circulation 2002; 106: 643-645.

  10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laako M: for the STOP-NIDDM trial research group. Acarbose Treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003; 290: 486-494.

  11. Hopkins PN, Heiss G, Ellison C, Province MA, Pankow JS, Eckfeldt JH, Hunt SC: Coronary heart disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case-control comparison from the National Heart, Lung and Blood Institute Family Heart Study. Circulation 2003; 108: 519-523.

  12. Velázquez MO, Rosas PM, Lara EA, Pastelín HG, Grupo ENSA 2000, Castillo C, Attié F, Tapia CR: Prevalencia a interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México. Arch Cardiol Mex 2003; 73: 62-77.

  13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow up report on the diagnosis of Diabetes Mellitus. Diabetes Care 2003; 26: 3160-3167.

  14. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm L, et al: Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.

  15. Greenland P, Smith SC, Grundy SM: Improving coronary heart disease risk assessment in asymptomatic people. Role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104: 1863-1867.

  16. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Canon III RO, Criqui M, et al: Markers of inflammation and cardiovascular disease. Application in clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.

  17. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group: Is the current definition for Diabetes relevant to mortality risk from all causes and cardiovascular and non cardiovascular diseases? Diabetes Care 2003; 26: 688-696.

  18. Hjemdahl P: Stress and the Metabolic Syndrome. An interesting but enigmatic association. Circulation 2002; 106: 2634-2636.

  19. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA: for the Conference participants. Clinical Management of Metabolic Syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation 2004; 109: 551-556.

  20. Reilly MP, Rader DJ: The Metabolic Syndrome. More than the sum of its parts? Circulation 2003; 108: 1546-1551.




2020     |     www.medigraphic.com